Drug intelligence / Profile preview

1-tert-butyl-3-(4-chloro-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine

Development stage
Preclinical
Modality
Small Molecules
01

Overview

A synthetic small molecule inhibitor primarily known as PP2. It is a potent and selective inhibitor of Src family tyrosine kinases (including Src, Lck, Fyn, and Yes), with additional activity against other kinases such as Abl and p38 MAP kinase. It is widely used in research to study signal transduction pathways involving these kinases but has not been approved for clinical use. The compound is considered experimental and has not advanced beyond preclinical or early-stage research phases. Its mechanism involves competitive inhibition at the ATP-binding site of target kinases.

Other names
1-Tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yamine1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amino4-amino-5-(4-chlorophenyl)-7-(tert-butyl)pyrazolo[3,4-d]pyrimidine
02

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)FYN (Proto-oncogene tyrosine-protein kinase Fyn)LYN (LYN proto-oncogene, Src family tyrosine kinase)MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on 1-tert-butyl-3-(4-chloro-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-tert-butyl-3-(4-chloro-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call